The diabetes drug semaglutide, known as Ozempic, has shown positive effects in patients with chronic kidney damage and obesity. A study led by Hiddo L. Heerspink of the University Medical Center Groningen found that the drug reduced protein in urine, kidney inflammation, and blood pressure. Participants also lost weight. The drug, which is primarily used for weight loss, has been shown to benefit those with kidney damage. The study, published in Nature Medicine, suggests that semaglutide has both direct and indirect effects on the kidneys. Further research is needed to explore its potential impact on dialysis, kidney transplants, and patients without obesity.
Source link
Diabetes drug semaglutide proves beneficial for patients with chronic kidney damage and obesity
